Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2009, Vol. 14 ›› Issue (11): 1296-1299.

Previous Articles     Next Articles

Study on IL-12, IL-10 expression of infants with none or low response to recombinant hepatitis B vaccine stimulated by bacillus Calmette-Guerin

DI Jun-bo, CHEN Yi-ping, XU Zhi-wei   

  1. Department of Infection, YuYing Children's Hospital Affiliated to Wenzhou Medical College, Wenzhou 325027, Zhejiang, China
  • Received:2009-08-27 Revised:2009-11-05 Published:2020-10-26

Abstract: AIM: To investigate the efficacy of Bacillus Calmette-Guerin (BCG) on IL-12, IL-10 expressions of infants with none or low response to recombinant hepatitis B vaccine. METHODS: The geometric mean titer (GMT) of anti-HBs was tested by radioimmunity assay after hepatitis B vaccine stimulation, selected 60 cases with non-or low-response(GMT <100 UL), who were divided into two groups, one group was injected by BCG, the concentrations of IL-10, IL-12 were detected by ELISA. RESULTS: BCG could significantly stimulate infants with none or low response to recombinant hepatitis B vaccine to product IL-12 and IL-10 associated cytokines, the enhancement was course-dependent.Compared with the control group, the GMT of anti-HBs was significantly higher than that in the Bacillus Calmette-Guerin injection group. CONCLUSION: BCG might be an effective adjuvant to induce cellular immune response via the enhancement of IL-12 and IL-10 of infants with none or low response to recombinant hepatitis B vaccine.

Key words: Bacillus Calmette-Guerin, recombinant hepatitis B vaccine, IL-12, IL-10

CLC Number: